High-purity magnesium lithospermate B and preparation method therefor

Patent metadata

Field	Value
Publication number	US-10259798-B2
Application number	US-201515301265-A
Country	US
Kind code	B2
Filing date	Feb 9, 2015
Priority date	Apr 1, 2014
Publication date	Apr 16, 2019
Grant date	Apr 16, 2019

Abstract

The present invention relates to a method for preparing magnesium lithospermate B. The method is characterized in that: magnesium lithospermate B is extracted or purified from a Salvia miltiorrhiza plant material or a Salvia miltiorrhiza extract in the presence of an added magnesium salt. The present invention also relates to a high-purity magnesium lithospermate B product prepared by the method of the present invention, wherein the content of magnesium lithospermate B is more than 95% by weight.

First claim

We claim:

1. A process for preparing magnesium lithospermate B, comprising:
a) obtaining a Salvia miltiorrhiza liquid extract by extracting a Salvia miltiorrhiza plant material with a first alcohol-water solution, and
b) separating the Salvia miltiorrhiza liquid extract via chromatography on macroporous absorption resin, wherein a second alcohol-water solution and a third alcohol-water solution is used for elution, collecting an eluate containing magnesium lithospermate B; concentrating the eluate to give a concentrated eluate, adjusting the pH value of the concentrated eluate to 3-7, and then extracting with an organic solvent to give a raffinate comprising magnesium lithospermate B;
wherein a magnesium salt is added into at least one of the following: the first alcohol-water solution in a), the Salvia miltiorrhiza liquid extract in b), the second alcohol-water solution in b), or the third alcohol-water solution in b).

2. The process according to claim 1 , wherein the magnesium salt is one or more of the following compounds: MgSO 4 , Mg(Ac) 2 , MgCl 2 , MgBr 2 , MgCO 3 , and Mg(HCO 3 ) 2 .

3. The process according to claim 1 or 2 , wherein the amount of the added magnesium salt is 5-200 mg per 100 g of the Salvia miltiorrhiza plant material or the Salvia miltiorrhiza extract.

4. The process according to claim 3 , wherein the organic solvent is selected from C 3 -C 6 alcohols, C 1 -C 6 alkyl C 1 -C 3 carboxylates, and di(C 1 -C 5 alkyl)ethers.

5. The process according to claim 4 , wherein the organic solvent is one or more selected from the following solvents: n-butyl alcohol, methyl acetate, ethyl acetate, propyl acetate, butyl acetate, methyl t-butyl ether, and diethyl ether.

6. The process according to claim 4 or 5 , further comprising concentrating the raffinate comprising magnesium lithospermate B, follow by alcohol-precipitating, filtrating, and drying to give a magnesium lithospermate B solid.

7. The process according to claim 6 , wherein the solvent used for alcohol-precipitating is ethanol or an aqueous ethanol solution.

8. The process according to claim 1 , wherein the first alcohol-water solution and the second alcohol-water solution are the same or different, and are independently selected from aqueous solutions of C 1 -C 4 alcohol with a concentration of 0-80%.

9. The process according to claim 1 , wherein the third alcohol-water solution is selected from aqueous solutions of C 1 -C 4 alcohol with a concentration of 0-80%.

10. The process according to claim 1 , further comprising concentrating the Salvia miltiorrhiza liquid extract to give a concentrated Salvia miltiorrhiza liquid extract.

11. The process according to any one of claims 1 , 2 , 3 , 4 - 9 , and 10 , wherein the macroporous resin comprises one or more of the following resins: HP20, HPD-80, HPD-100, HPD-100B, HPD-200A, HPD-300, HPD-450, HPD-722, HPD-826, ADS-5, ADS-8, ADS-21, D101, AB-8, and 1300-I.

Assignees

• Shanghai Inst Materia Medica Cas
• Shanghai Green Valley Pharmaceutical Co Ltd

Inventors

• Xuan Lijiang
• Wang Yiping
• Song Weibin
• Chen Chunguang
• Li Dingxiang
• Zhou Xiaoyu
• Gu Yunlong
• Hu Liang
• Zhao Jing
• Xu Wenwei
• Wang Shumei

Classifications

• A61P39/06

  Free radical scavengers or antioxidants · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• C07D307/86 Primary

  with an oxygen atom directly attached in position 7 · CPC title